2. Search Result
Search Result
Results for "

paclitaxel-resistant lung cancer

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-127079
    Epothilone F

    		Microtubule/Tubulin Cancer
    Epothilone F is a 16-membered macrolide microtubule-targeting agent. Epothilone F exhibits significant anticancer activity, and it particularly exerts effective inhibitory effects on paclitaxel-resistant cancer cells. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells and drug-resistant ovarian cancer cells, and it has been widely used in cancer-related research .
    Epothilone F
  • HY-106219
    BMS 275183

    		Microtubule/Tubulin P-glycoprotein Cancer
    BMS 275183 is a potent, orally active analogue of Paclitaxel (HY-B0015). BMS 275183 can stabilize microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is active in vitro against Paclitaxel-resistant tumors including those harboring tubulin mutations or overexpressing P-glycoprotein. BMS 275183 can be used for cancer research, such as non-small cell lung cancer (NSCLC) and prostate carcinoma .
    BMS 275183
  • HY-183143
    Lss-11

    		Topoisomerase Apoptosis TNF Receptor PARP STAT P-glycoprotein Cancer
    Lss-11 is a topoisomerase inhibitor. LSS-11 enhances cell death in cancer cells by inducing apoptosis through increasing the DR5 protein level and PARP1 cleavage. LSS-11 dose-dependently reduces STAT3 phosphorylation, downregulates its target genes MDR1 and MRP1, reduces P-gp protein expressionwithout affecting P-gp transport function. Lss-11 is a chemosensitizer and shows synergistic anticancer effect with Paclitaxel (HY-B0015). Lss-11 can be used for the research of paclitaxel-resistant lung cancer .
    Lss-11
  • HY-181550A
    CYP1B1-IN-14 TFA

    		Cytochrome P450 P-glycoprotein Cancer
    CYP1B1-IN-14 TFA is a metabolically stable hCYP1B1 competitive inhibitor with an IC50 of 1.32 nM and a Ki of 0.72 μM. CYP1B1-IN-14 TFA reverses the resistance of cancer cells to Paclitaxel (HY-B0015). CYP1B1-IN-14 TFA acts synergistically with Paclitaxel (HY-B0015) to inhibit tumor growth in xenograft models without obvious toxicity. CYP1B1-IN-14 TFA can be used for the research of cancers such as paclitaxel-resistant lung cancer .
    CYP1B1-IN-14 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: